Cite
HARVARD Citation
Zhang, J. et al. (2018). Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Annals of oncology. pp. 1741-1747. [Online].